Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Jmk2454on Jul 22, 2019 8:20pm

45 Views

Post# 29948975

RE:RE:RE:RE:Kalytera PT $0.10 to $0.15

Jmk2454 wrote:

ALLFACTS wrote: Not good. But it hasn't been all pots of gold at the end of the rainbow. Kalytera Therapeutics, Inc. (OTCQB:KALTF) (KLY.V) has so far been a place where investors' money goes to die since it completed a reverse merger to list in Canada at the end of 2016. The stock price has decreased approximately 95% since Kalytera started trading and 90% since the start of 2018:

Lbs said that in the article but you must have missed the part where he said he has a large position in the company because he believes they are going to be successful - “allfacts”.

Sorry - The writer said . . .

Bullboard Posts

Defence Therapeutics touts anticancer treatment and immune booster